On August 1 2023, STERIS PLC ($NYSE:STE) reported its financial results for the first quarter of FY2024, which ended on June 30 2023. The total revenue generated for this quarter was USD 1284.5 million, a year-on-year increase of 11.1%. Net income also rose by 11.0%, reaching USD 123.6 million.
At the opening bell, STERIS PLC stock was priced at $223.8, and ended the day at $224.0, a slight decline of 0.7% from its prior closing price of $225.6. These results come on the heels of STERIS PLC’s strong performance over the past year and represent a positive start to fiscal year 2024. With its strong financial results and promising outlook, STERIS PLC is well-positioned to continue delivering value for its shareholders for years to come. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Steris Plc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Steris Plc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Steris Plc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Steris Plc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we have done an analysis of STERIS PLC‘s wellbeing to help potential investors make an informed decision. According to our Risk Rating, STERIS PLC is a medium risk investment in terms of financial and business aspects. We have detected two risk warnings in their income statement and balance sheet, so if you’re interested to know more, please register with us. We will provide an in-depth look at the company and its performance to help you decide whether to invest or not. More…
Risk Rating Analysis
Star Chart Analysis
The company’s main competitors are Fonar Corp, Stryker Corp, and Dynatronics Corp.
Fonar Corporation is a holding company, which engages in the design, manufacture, sale, and service of magnetic resonance imaging (MRI) scanners. It operates through the following segments: Upright Multi-Position MRI; Stand-Up MRI; and Recurring Revenue. The Upright Multi-Position MRI segment designs, manufactures, and sells Upright Multi-Position MRI scanners. The Stand-Up MRI segment designs, manufactures, sells, and services Stand-Up MRI scanners. The Recurring Revenue segment provides service contracts, technical support, and parts sales. The company was founded by Stanley C. Krulick in 1978 and is headquartered in Melville, NY.
Stryker Corporation is one of the world’s leading medical technology companies. It offers a wide range of medical devices and services, including orthopedics, neurotechnology, and medical imaging. It has more than 87,000 employees worldwide.
Dynatronics Corp is a medical device company that manufactures and markets physical therapy products and solutions. The company’s products are used by physical therapists, occupational therapists, athletic trainers, and other healthcare professionals. Dynatronics Corp has a market cap of 8.73M as of 2022, a Return on Equity of -10.7%. The company’s products are sold in the United States and internationally.
STERIS PLC‘s financial performance for the first quarter of FY2024 has been strong. Total revenue grew 11.1%, to USD 1284.5 million, while net income rose 11.0%, to USD 123.6 million. These results reflect the company’s ability to increase sales and manage expenses.
The outlook for STERIS PLC remains positive, with further growth expected in the coming quarters. Investors should consider this stock for its strong earnings potential and solid financial position.